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We describe a novel form of tumor cell plasticity characterized by reversible adaptive plas-
ticity in murine and human neuroblastoma. Two cellular phenotypes were defined by their
ability to exhibit adhered, anchorage dependent (AD) or sphere forming, anchorage inde-
pendent (AI) growth. The tumor cells could transition back and forth between the two
phenotypes and the transition was dependent on the culture conditions. Both cell phe-
notypes exhibited stem-like features such as expression of nestin, self-renewal capacity,
and mesenchymal differentiation potential. The AI tumorspheres were found to be more
resistant to chemotherapy and proliferated slower in vitro compared to the AD cells. Iden-
tification of specific molecular markers like MAP2, β-catenin, and PDGFRβ enabled us to
characterize and observe both phenotypes in established mouse tumors. Irrespective of
the phenotype originally implanted in mice, tumors grown in vivo show phenotypic het-
erogeneity in molecular marker signatures and are indistinguishable in growth or histologic
appearance. Similar molecular marker heterogeneity was demonstrated in primary human
tumor specimens. Chemotherapy or growth factor receptor inhibition slowed tumor growth
in mice and promoted initial loss of AD or AI heterogeneity, respectively. Simultaneous tar-
geting of both phenotypes led to further tumor growth delay with emergence of new unique
phenotypes. Our results demonstrate that neuroblastoma cells are plastic, dynamic, and
may optimize their ability to survive by changing their phenotype. Phenotypic switching
appears to be an adaptive mechanism to unfavorable selection pressure and could explain
the phenotypic and functional heterogeneity of neuroblastoma.
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INTRODUCTION
Despite extensive research, recurrent pediatric neuroblastoma
remains an elusive disease with poor prognosis. Neuroblas-
toma, the most common extracranial solid tumor of childhood
includes half of all neoplasms diagnosed in the first year of
life (Gurney et al., 1997; Brodeur, 2003). It displays divergent
behavior ranging from spontaneous regression to inevitable pro-
gression and death. Neuroblastoma is often responsive to stan-
dard treatments, resulting in tumor reduction, and a state of
minimal residual disease (Matthay et al., 1999; De Bernardi
et al., 2003). However, high-risk cases of neuroblastoma usu-
ally recur and are most often fatal (Tajiri et al., 2001; Woods
et al., 2002; Maris, 2010; Yalcin et al., 2010; Jiang et al., 2011).
The frequency of relapse and subsequent failure of treatment
spurred the need to better understand the mechanism of resis-
tance with the ultimate aim of designing more effective targeted
therapies.
Tumor cell plasticity is the ability of a tumor cell to adapt to its
environment and change its phenotype. This plasticity may allow
tumor cells to reversibly turn on and off specific markers. It is
described in several tumor types, including melanoma (Hoek et al.,
2008) and glioblastoma (Bonavia et al., 2011). Tumor cell adapta-
tion is an important phenomenon as it is believed to constitute
a major mechanism enabling tumors to evade surveillance of
the immune system, survive unfavorable conditions, or escape
radio- or chemotherapy. The human neuroblastoma cell line SK-
N-SH revealed phenotypic plasticity featuring morphological and
biochemical inter-conversion in culture (Ross et al., 1983). The
cell lines SH-SY-5Y and SK-N-MC demonstrated adaptation to
hypoxia in which the neuroblastoma cells transition from an
adherent phenotype to a highly migratory and invasive cell type
(Poomthavorn et al., 2009). The dynamic behavior of tumor cells
has been shown in other tumor models like glioblastoma (Jiang
et al., 2011) and melanoma (Roesch et al., 2010). The major
mechanism considered for tumor adaptation is genetic instabil-
ity followed by the selection of resulting phenotypes that adapt
best to the environmental conditions. This represents a unidirec-
tional path resulting in adapted tumor cell phenotypes that could
be characterized by increased aggressiveness, metastatic potential,
or resistance to therapeutic interventions. In this manner, tumor
development can be regarded as a process of Darwinian evolution
(Marusyk and Polyak, 2010). The cellular source of this evolu-
tion could be rare cancer stem cells giving rise to tumor cells with
high-risk characteristics (Lonardo et al., 2010; O’Brien et al., 2010).
Although the existence of a minor subset of cancer cells that have
the unique ability to self-renew has been demonstrated by multiple
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research groups, the concept of cancer stem cells remains a subject
of debate.
Another mechanism that could afford tumors aggressive, resis-
tant behavior, and heterogeneity is an epithelial to mesenchymal
transition (EMT; Creighton et al., 2009). In this process, epithelial
cells detach and acquire mesenchymal characteristics facilitat-
ing cell migration. Once migrated, these cells can either remain
mesenchymal or de-differentiate into epithelial cells by a process
known as mesenchymal to epithelial transition (MET; Thiery and
Sleeman, 2006; Creighton et al., 2010). These findings imply that
tumor cell plasticity can be achieved by cellular adaptation at the
single cell level, rather than through selection of particular tumor
variants. The findings of invasive and proliferative gene expres-
sion signatures of melanoma growing in vivo (Hoek et al., 2008)
suggests that other forms of tumor cell transitions exist that need
not be based on (de)differentiation.
We describe a novel form of tumor cell plasticity characterized
by reversible adaptive phenotypic transformation. Two defined
neuroblastoma phenotypes both having stem-like characteristics
were induced using distinct culture conditions. Identification of
specific molecular markers enabled us to observe both phenotypes
in tumors growing in vivo, irrespective of the phenotype originally
inoculated in mice. This finding explains tumor heterogeneity
and establishes that reversible or adaptive phenotypic conver-
sion occurs in vivo. Facing chemotherapeutic intervention, tumors
in vivo temporarily showed preference for the chemo-resistant
phenotype. Simultaneous targeting of both tumor cell phenotypes
in a mouse model of neuroblastoma resulted in delay in tumor
growth and emergence of new phenotypes. These observations
describe adaptive phenotypic transformation as a mechanism of
tumor cell plasticity that enables tumors to escape unfavorable
environmental conditions.
MATERIALS AND METHODS
ANIMALS
Female A/J mice (6 weeks old) were purchased from Jackson Lab-
oratory (Bar Harbor, ME, USA). The animals were acclimated for
4–5 days prior to tumor challenge. All procedures were approved
by Institutional Animal Care and Use Committee.
MURINE AND HUMAN CELL LINES
Neuro2a is the murine neuroblastoma cell line derived from
AJ mice. IMR-32 and SK-N-SH are human cell lines derived
from MYCN amplified and non-amplified neuroblastoma tumors,
respectively. All cell lines were purchased from ATCC (Manas-
sas, VA, USA). Neuro2a and SK-N-SH cells were cultured in
DMEM (Gibco, Carlsbad, CA, USA) while IMR-32 cells were cul-
tured in EMEM (Lonza, Walkersville, MD, USA); both media
containing 10% fetal bovine serum (FBS, Gibco), 0.5% peni-
cillin/streptomycin, and 10% l-glutamine. The cells grew as
anchorage dependent (AD) cells. Anchorage independent (AI)
tumorspheres from each cell line were grown in NeuroCult com-
plete media consisting of NeuroCult Neural Stem Cell (NSC)
Basal medium, 1/10 NeuroCult NSC Proliferation supplements,
20 ng/ml EGF, 10 ng/ml bFGF, and 2µg/ml Heparin. NeuroCult
media, supplements, and growth factors were all purchased from
Stem Cell Technologies (Vancouver, BC, Canada).
CELL CYCLE ANALYSIS
The AD and AI cells were harvested from culture medium, washed
in cold PBS, and fixed in 70% ethanol at−20˚C for 2 h. Cells were
centrifuged, washed with cold PBS, and resuspended in propid-
ium iodide mix (40µg/ml PI and 0.1 mg/ml RNAse in PBS). After
30 min incubation at 37˚C cells were analyzed in FACSCalibur
(Becton Dickinson, San Jose, CA, USA).
MTT ASSAY
Metabolic activity of the proliferating cells after Doxorubicin
(100 ng/ml) treatment was determined by the colorimetric
absorbance of the MTT assay at 24, 48, and 72 h post treatment.
Briefly, control and treated AD and AI cells (5000 cells/well) were
plated in 96-well plates and MTT [3-(4,5-dimethylthiazolyl-2)-
2,5-diphenyltetrazolium bromide] (Sigma, St. Louis, MO, USA)
was added to each well at a concentration of 10 mg/ml. After 4 h,
the purple formazan formed from the reduction of MTT was dis-
solved in DMSO and the absorbance was measured at 540 nm in
a plate reader.
APOPTOSIS ASSAY
Control and irradiated AD and AI cells were analyzed for apop-
tosis by flow cytometry. Briefly, cells were washed with 1×
Annexin binding buffer and stained with APC-conjugated Annex-
inV for 20 min followed by 7-AAD for 5 min. Cells were analyzed
immediately for AnnexinV/7-AAD expression using FACSCalibur.
DIFFERENTIATION ASSAY
Mouse and human AD and AI cells were compared for their
multi-lineage differentiation potential following placement in
poly-d-lysine coated coverslips with differentiation media for
10–14 days. Fixed cells were stained with markers of stem cells
(nestin), neurons (βIII-tubulin, Tuj1), oligodendrocytes (O4), and
astrocytes (glial fibrillary acidic protein, GFAP) as described in
Immunofluorescence assay.
IN VIVO TUMOR GROWTH AND DRUG TREATMENTS
Mice were injected subcutaneously with 1× 106 AD or AI Neuro2a
cells and divided into four groups; AD-treated, AI-treated, AD-
untreated, and AI-untreated. For the chemotherapeutic treat-
ment regimen, doxorubicin (2.5 mg/kg) was administered twice
a week intraperitonealy (i.p.) and metformin daily in drink-
ing water to the treated groups starting on post-inoculation day
1. For inhibiting the growth factor receptors, a combined dose
of erlotinib (EGFR inhibitor, 50 mg/kg) and PD173074 (FGFR
inhibitor, 50 mg/kg) was administered i.p. every alternate day to
the treated groups starting on post-inoculation day 1. To treat the
mice simultaneously with chemotherapy and growth factor inhi-
bition, doxorubicin, erlotinib, and PD173074 were administered
twice a week and metformin was given daily in drinking water
starting on post-inoculation day 1. Tumor growth was monitored
on alternate days. Tumors reaching 5, 10, or 15 mm in diameter
were resected. Tumors were either fixed in 4% paraformaldehyde
(PFA) and frozen for immunofluorescence staining or fixed in
formalin and processed for immunohistology or digested with col-
lagenase/dispase/DNAse for flow cytometric analysis. The digested
tumor was also used to extract protein for Western blot analysis.
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IMMUNOFLUORESCENCE ASSAY
Ten micron frozen sections of 10 and 15 mm diameter size
tumors or the cultured cells on coverslips were subjected to
inmmunofluorescence assay using the antibodies: rabbit anti-
nestin (1:500, Abcam, Cambridge, MA, USA), doublecortin (Dcx,
1:500, Abcam), neural cell adhesion molecule (NCAM, 1:1000,
Cell Signaling, Danvers, MA, USA), β-catenin (1:1000, Cell Sig-
naling), survivin (1:1000, Cell Signaling), and platelet derived
growth factor receptor beta (PDGFRβ, 1:100, Santa Cruz Biotech-
nology, Santa Cruz, CA, USA), mouse anti-Tuj1 (1:500, Cov-
ance, Princeton, NJ, USA), O4 (1:1000, Stem Cell Technologies),
GFAP (1:1000, Sigma), and microtubule associated protein-2
(MAP2, 1:1000, Sigma). The secondary antibodies used were
AlexaFluor 488, AlexaFluor 546, and AlexaFluor 633 conjugated
goat anti-rabbit or anti-mouse IgG (1:200, Invitrogen, Carlsbad,
CA, USA). All fluorescent images were taken on aLSM confo-
cal microscope (Carl Zeiss Inc., Germany) using 20× or 40×
objectives.
TUMOR HISTOLOGY
The formalin fixed tumors grown from AD or AI Neuro2a cells
were sectioned by a pathologist and H&E staining was performed
to examine for histopathologic differences between the tumors
derived from the two phenotypes of the Neuro2a cells.
WESTERN BLOT ANALYSIS
Protein concentration was determined according to manufac-
turer’s instruction using BCA Protein Assay Kit (Pierce, Rock-
ford, IL, USA). Twenty micrograms of protein homogenate were
loaded per well for electrophoresis after which the proteins were
transferred to polyvinylidene difluoride membranes and blocked
with 5% milk. The blots were incubated overnight with a 1:1000
dilution of rabbit anti-nestin, Dcx, NCAM, β-catenin, survivin,
PDGFRβ, Telomerase, Gli1 (Santa Cruz biotechnology), vascu-
lar endothelial growth factor (VEGF, Santa Cruz Biotechnol-
ogy), and mouse anti-MAP2 and VEGFR2 (Santa Cruz Biotech-
nology) followed by HRP-conjugated anti-rabbit or anti-mouse
secondary antibodies (1:2000, Pierce). Blots were developed by
chemiluminescence using SuperSignal Kit (Pierce). Rabbit anti-
GAPDH (Cell Signaling) was used as a control for protein loading
variations.
FLOW CYTOMETRIC PHENOTYPING
The digested tumor or the cultured AD and AI cells were phe-
notyped according to the slightly modified protocols of Leung
et al. (1992) and Daniel et al. (2008). Briefly, the cells were cen-
trifuged at low speed, fixed in 4% PFA, washed with PBS con-
taining 2% FBS (FACS buffer), and resuspended in 100µl FACS
buffer containing 0.03% TritonX-100. The cells were incubated
with primary antibodies (nestin, MAP2, β-catenin, and PDGFRβ)
for 30 min at room temperature. No TritonX-100 was added
for PDGFRβ staining. The cells were washed with FACS buffer
and incubated with FITC-conjugated goat anti-rabbit and APC-
conjugated goat anti-mouse secondary antibodies for 20 min.
After additional washes, the cells were analyzed in FACSCal-
ibur. Tumor cells were gated from forward scatter/side scatter
plots.
STATISTICAL ANALYSIS
Data are presented as mean± S.D. Two-tailed Student’s t -test
was used to determine statistical significance between groups.
A probability level of p< 0.05 was considered to be statistically
significant.
RESULTS
REVERSIBLE PHENOTYPIC ADAPTATION IN NEUROBLASTOMA
Mouse (Neuro2a) and human (IMR-32 and SK-N-SH) cell lines,
cultured in D10 media exhibited an AD phenotype characterized
by growth in a monolayer. Transfer to serum-free NeuroCult com-
plete (NC) media supplemented with EGF and FGF induced an
AI phenotype, characterized by detachment of cells and forma-
tion of floating tumorspheres (Figure 1A). AI cells from all the
cell lines readily reformed tumorspheres when cultured in NC
media, but adhered and formed monolayers when cultured in
the D10 media (Figure 1B). Thus, neuroblastoma cultures facing
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B  
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AI 
   Neuro2a 
   SK-N-SH 
   IMR-32 
AD AI AD 
AD 
FIGURE 1 | Reversible adaptive plasticity of neuroblastoma cell lines.
(A) Neuro2a, IMR-32, and SK-N-SH cells cultured in DMEM+10% FBS
(D10) or Neurocult complete (NC) medium formed a monolayer of
anchorage dependent (AD) adhered cells or anchorage independent (AI)
tumorspheres, respectively. (B) Dissociated AI cells, originally derived from
AD cells readily reversed their phenotype and formed AD monolayers when
cultured in the D10 medium. Images acquired with 20× objective.
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distinct growth promoting conditions can transition to and from
two distinct phenotypes which are defined by tumor cell adher-
ence characteristics. We have observed a similar phenomenon of
adaptive growth patterns in melanoma and rhabdomyosarcoma
cell lines (Unpublished data).
Anchorage independent phenotypes grew slower than AD phe-
notypes in all cell lines as indicated by cell cycle analysis and MTT
assay (Figures 2A,B and 3A–C). The AD cells were also found to
be more sensitive to the chemotherapeutic agent doxorubicin than
the AI cells (Figure 3D).
STEM CELL-LIKE QUALITIES ARE PRESENT IN BOTH AD AND AI
PHENOTYPES
Cancer stem cell properties include self-renewal capacity, potent
in vivo tumorigenic activity, and an undifferentiated state with the
ability to differentiate (Al-Hajj et al., 2003; Singh et al., 2003; Dean
et al., 2005; Bao et al., 2006). The phenotypic transition could
be a property of a rare cell subpopulation within the cell lines
(such as cancer stem cells) or a general cell property. To evaluate
these possibilities we performed a self-renewal assay that is con-
sidered a stem-like quality. AI and AD forms of Neuro2a cells were
dissociated and reseeded at a limiting dilution. Cells cultured in
NC media reformed tumorspheres, while those cultured in D10
formed monolayers of adhered cells (Figure 4A). The efficiency of
clonal growth of cells seeded at 1 cell/well was similar in AI and AD
phenotypes, suggesting self-renewal potential in both phenotypes
(Figure 4B).
We also assessed the differentiation potential of AI and AD
phenotypes as another characteristic of stem cells. Staining with
neuronal (Tuj1), oligodendrocyte (O4), and astrocyte (GFAP)
markers revealed differentiation into all three lineages for both
phenotypes of Neuro2a (Figures 4C,D). The human cell lines dif-
ferentiated readily into neurons and oligodendrocytes, but not
into astrocytes (Figure 5A). Immunoflourescence, Western blot,
and flow cytometric analysis indicate that the stem cell marker,
nestin is expressed in both AD and AI phenotypes (Figures 4D–F
and 5B,C). Furthermore, expression of other suggested stem cell
markers (Sox2, CD133, and CD44) were not different between
the AI and AD phenotypes (data not shown). Taken together,
neither phenotype appears specifically enriched for putative can-
cer stem cells, but both have stem-like qualities. In addition, the
phenotypic conversion does not alter stem-like characteristics of
Neuro2a cells.
THE NEURO2a PHENOTYPIC ADAPTATION IS DISTINCT FROM
EPITHELIAL TO MESENCHYMAL TRANSITION
Loss of E-cadherin and upregulation of β-catenin, vimentin,
and SNAIL are classic characteristics for EMT. E-cadherin was
not detected in either AI or AD phenotype while vimentin and
SNAIL were equally abundant in both (Figures 4G and 5D).
Thus, besides the fact that neuroblastoma is not an epithelial
tumor, the reversible phenotypic conversion described is incon-
sistent with the molecular changes observed in either EMT
or MET.
THE TWO NEUROBLASTOMA PHENOTYPES EXPRESS DISTINCT
MOLECULAR SIGNATURES IN VITRO
To determine whether the AI and AD phenotypes of Neuro2a
cells have distinct molecular markers, we analyzed expression of
eleven proteins that play a vital role in neuroblastoma home-
ostasis. These included proteins regulating proliferation (β-
catenin/FZD1, SHH/Gli1/PTCH1, TrkB/BDNF, PDGFR), apop-
tosis (FZD1, Gli1), chemo-resistance (FZD1, Telomerase), angio-
genesis (VEGF/VEGFR, PDGFRβ, SHH), metastasis (SHH, MAP2,
TrkB), adhesion and migration (NCAM, TrkB, Dcx), and differ-
entiation and neurite extension (MAP2, Dcx) (Eggert et al., 2000;
Oltra et al., 2005; Nakamura et al., 2006; Flahaut et al., 2009; Korja
FIGURE 2 | Cell cycle analysis of AD andAI phenotypes of neuroblastoma
cell lines. (A) Cell cycle analysis of Neuro2a, SK-N-SH, and IMR-32 cells using
propidium iodide. (B) Graphical representation of the cell cycle analysis
reveals that AI phenotype of Neuro2a and SK-N-SH cells has significantly
fewer numbers of cells in S-phase compared to their AD phenotype. Data
points expressed as mean±S.D. (n= 3). *p< 0.01 by Student’s t -test.
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FIGURE 3 | Effect of doxorubicin on metabolic activity and apoptosis of
neuroblastoma cell lines. MTT assay of the untreated and doxorubicin
treated Neuro2a (A), SK-N-SH (B), and IMR-32 (C) cells of either AD or AI
phenotype revealed slower metabolic activity of the AI cells. Doxorubicin
lowered the metabolic activity of both the phenotypes of all cell lines. (D)
Graphical representation of the apoptosis assay at 24, 48, and 72 h following
doxorubicin (Dx; 0, 0.01, and 0.1µg/ml) treatment shows that the AI cells are
more resistant to doxorubicin than the AD cells. The change in viability
between the treated and untreated groups of AI cells is less for all time points
and drug doses. Data points expressed as mean±S.D. (n=3).
et al., 2009; Krishnan et al., 2009; Bahnassy et al., 2010; Oue et al.,
2010; Souzaki et al., 2010; Wesbuer et al., 2010; Zhang et al., 2010;
Schiapparelli et al., 2011). Western blot analysis revealed differ-
ences in expression of PDGFRβ, MAP2, Dcx, NCAM, survivin,
and β-catenin (Figures 6A,B), thereby identifying these mole-
cules as potential unique markers of AI or AD phenotypes. To
test the value of these molecules as markers of in vivo cellular
commitment to AD or AI phenotypes we performed immuno-
fluorescence microscopy. This analysis confirmed the findings for
MAP2, β-catenin, and PDGFRβ, while staining for Dcx, NCAM,
and survivin did not discriminate (Figure 6C). Flow cytomet-
ric analysis confirmed differences in the expression of MAP2,
β-catenin, and PDGFRβ while all neuroblastoma cells were nestin
positive (Figure 6D). These results showed that Nestin+MAP2+
cells are indicative of the AD phenotype while Nestin+MAP2−
are markers of the AI phenotype.
TUMOR CELL HETEROGENEITY IN VIVO
To determine the in vivo representation and stability of the in vitro
phenotypes, mice were inoculated separately with Neuro2a cells
of AD or AI phenotypes. Nestin, MAP2, β-catenin, and PDGFRβ
expression were analyzed in tumors reaching 5, 10, and 15 mm
in diameter. Flow cytometry and Western blot analyses revealed
similar abundance of each protein in tumors of corresponding
sizes irrespective of the phenotype injected (Figures 7A,B). This
finding suggests that either both AI and AD phenotypes were
present in vivo, or that a third phenotype containing both AI
and AD markers was predominant in vivo. To distinguish between
these possibilities we stained frozen tumor sections with nestin,
MAP2, PDGFRβ, and β-catenin specific antibodies. This analysis
showed heterogeneity of cells in situ (Figure 7C). In light of ubiq-
uitous nestin expression, scattered areas with differential MAP2,
PDGFRβ, and β-catenin staining represent Neuro2a cells of AD
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FIGURE 4 | Stem cell-like properties of AD andAI phenotypes of
mouse neuroblastoma cell line. (A) Dissociated AI or AD phenotypes
of Neuro2a cells reseeded at limited dilution in NC or D10 media
exhibited self-renewal capability over time by reforming tumorspheres or
growing as adhered cells, respectively. (B) Graphical representation of
the percent self-renewal capacity of the AD and AI cells as measured by
the percent of wells (seeded at 1 cell/well) growing adherent cells or
tumorspheres, respectively. (C) Neuro2a cell-derived AI tumorspheres
and AD adhered cells were allowed to differentiate followed by
immunostaining for stem cells (nestin), neurons (Tuj1), oligodendrocytes
(O4), and GFAP (astrocytes). (D) Graphical representation of the percent
immunopositive cells revealed multipotency and ubiquitous expression
of nestin for both phenotypes. Data points expressed as mean±S.D.
(n=3). (E)Western blot analysis supports the abundant expression of
nestin by both AD and AI phenotypes of Neuro2a cells. (F) Flow
cytometric analysis supports that nestin is a ubiquitous marker of both
tumor cell phenotypes. MFI, mean fluorescence intensity. (G)Western
blot analysis showing complete absence of E-cadherin and abundance of
vimentin and SNAIL proteins in both AD and AI phenotypes of neuro2a
cells. Scale bar, 100µm.
(MAP2) or AI (PDGFRβ and β-catenin) phenotype. This conclu-
sion is also supported by co-staining of nestin and MAP2 showing
both Nestin+MAP2+ and Nestin+MAP2− cells in tumors irre-
spective of their phenotype prior to inoculation (Figure 7C).
The pockets of cells with distinct phenotypes were not localized
to a specific region in the tumor mass, but seemed randomly
distributed (data not shown). Not surprisingly, the histopatho-
logic appearance (Figure 7D) and in vivo growth (Figure 7E) of
the tumors were also indistinguishable. Therefore, Neuro2a cells
driven to AI or AD phenotype in vitro display a tendency to tran-
sition, establish, and maintain an approximate 1:1 ratio of the two
phenotypes in vivo.
The coexistence of AI and AD phenotypes in vivo could be
unique to Neuro2a cells or cell lines in general, and may not be a
reflection of events that occur in primary neuroblastoma tumors.
To address this issue, frozen sections of three human neurob-
lastoma specimens were co-stained with nestin and MAP2 and
separately with PDGFRβ and β-catenin specific antibodies. This
analysis revealed similar heterogeneity of cells as seen in mouse
tumors indicating that phenotypic heterogeneity exists in primary
human neuroblastomas (Figure 8).
CHEMOTHERAPY ALTERS THE HETEROGENEITY OF THE TUMOR CELLS
IN VIVO
Since Neuro2A AI and AD phenotypes were differentially suscep-
tible to doxorubicin exposure in vitro, we sought to determine
the effects, if any, doxorubicin might exert on the Neuro2a phe-
notype of cells growing in vivo. Mice inoculated with AD and
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FIGURE 5 | Stem cell-like properties of AD andAI phenotypes of
human neuroblastoma cell lines. (A) SK-N-SH and IMR-32
cell-derived AI tumorspheres and AD adhered cells were allowed to
differentiate followed by immunostaining for stem cells (nestin),
neurons (Tuj1), oligodendrocytes (O4), and GFAP (astrocytes). Both the
phenotypes of each cell type differentiated into neurons and
oligodendrocytes but no astrocyte was detected. (B) Graphical
representation of the percent immunopositive cells revealed
multipotency and abundant expression of nestin for both the
phenotypes. Data points expressed as mean±S.D. (n=3). (C)
Western blot analysis supports the abundant expression of nestin by
both AD and AI phenotypes. (D)Western blot analysis showing
absence of E-cadherin and abundance of vimentin and SNAIL proteins
in both AD and AI phenotypes of human neuroblastoma cell lines.
AI forms of Neuro2a cells were treated with doxorubicin. Ini-
tial tumor growth was found to be slower in the doxorubicin
treated mice compared to the untreated mice (Figures 9A,B).
At an early stage (5 mm in diameter), doxorubicin treated AD
tumors maintained their heterogeneity similar to the untreated
tumor (Figure 10A); whereas the AI-tumors remained in AI form
and did not transition (Figure 10B). This observation shows that
doxorubicin initially prevented transition to the more sensitive AD
phenotype. Interestingly, as the tumors grew larger (10–15 mm in
diameter), they became resistant to doxorubicin, displayed faster
growth in vivo (Figure 9A), and both AD and AI forms were
reconstituted (Figure 11A).
Metformin added to doxorubicin prevents relapse in xenografts
induced by diverse cancer cell types including breast, prostate,
and lung cancer cell lines (Iliopoulos et al., 2011). We there-
fore extended our study to address the effects of combina-
tion therapy (doxorubicin plus metformin) on tumor cell het-
erogeneity. The combined effects were remarkably more sup-
pressive on tumor growth (Figure 9B) and also concurrently
prevented the AD phenotype from establishing itself in early
stage tumor formation as defined by the absence of MAP2+
cells irrespective of AD or AI inoculation (Figure 10C). The
cells remained in the AI form while they adapted to the slow-
growing, resistant phenotype (Figure 11B). These results show
that doxorubicin-based chemotherapeutic treatment is preferen-
tially effective on neuroblastoma cells of one phenotype and that
in response to treatment, tumors temporarily transition into the
more resistant phenotype. After chemo-resistance is established
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FIGURE 6 | Molecular markers differentiate AD andAI phenotypes of
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vital role in neuroblastoma homeostasis revealed differences in expression
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and AI phenotypes. (B)The table represents relative protein expression of
AD and AI cell types as determined by Western blot analysis. (C)
Immunofluoresence analysis in vitro demonstrated that MAP2 is
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overexpressed in AI cells compared to the AD cells. (D) Flow cytometric
analysis confirmed that MAP2 is expressed by the AD cells only, whereas
β-catenin and PDGFRβ are overexpressed in AI cells. Scale bar, 50µm.
MFI, mean fluorescence intensity.
and tumors rebound, the heterogeneity of the phenotypes is
re-established.
GROWTH FACTOR RECEPTOR INHIBITION TARGETS THE AI PHENOTYPE
OF THE TUMOR CELLS IN VIVO
As the chemotherapeutic agents tested targeted the AD phenotype,
we postulated that the AI phenotype could be targeted in vivo
by inhibiting the growth factors used to induce this phenotype
in vitro. Small molecule inhibitors of EGF (Erlotinib) and FGF
(PD173074) receptors in combination prevented the growth of
the AI phenotype in small tumors (5 mm) and resulted in tumors
primarily containing the AD phenotype (Nestin+MAP2+) irre-
spective of the AD or AI phenotype inoculated (Figure 10D).
EMERGENCE OF NEW PHENOTYPES FOLLOWING CHEMOTHERAPY
COMBINED WITH GROWTH FACTOR RECEPTOR INHIBITION
The collective findings showed that targeting either phenotype
drove the cells into the other type, suggested that simultaneously
targeting both phenotypes could prevent the reversible pheno-
typic adaptation from occurring. To test this hypothesis mice
were treated with doxorubicin (twice a week), metformin (daily),
Erlotinib (twice a week), and PD173074 (twice a week) starting
a day after their tumor challenge with AD or AI phenotypes of
Neuro2a cells. This combined therapy, significantly delayed the
initial onset of tumor growth for both phenotypes (Figure 9B),
but resulted in the emergence of newer phenotypes as evident
from the presence of unique/unfamiliar populations of MAP2+
and PDGFRβ+ cells (Figure 10E). Taken together these results
suggest that neuroblastoma tumor cells use their plastic adap-
tive phenotypic transformation as a tool to survive unfavorable
selection pressure.
DISCUSSION
We show that mouse and human neuroblastoma cells are capa-
ble of conversion between two distinct phenotypes dependent on
culture conditions, a transition we refer to as reversible adaptive
plasticity. Identification of several molecular markers of AI and
AD phenotypes allowed us to demonstrate that the reversible
adaptation occurs during tumor growth in vivo. Regardless of
which phenotype was used to inoculate mice, the resultant tumors
eventually contained cells with a heterogeneous distribution of
markers. Importantly, the distinct phenotypes exist in human
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FIGURE 7 | Neuroblastoma tumor cell heterogeneity in mouse model.
(A) Flow cytometric phenotyping analysis on mouse neuroblastoma
tumors of 10 mm diameter showed no remarkable difference in the
expression of MAP2, β-catenin, and PDGFRβ in the two forms of tumor.
MFI, mean fluorescence intensity. (B)Western blot analysis on mouse
neuroblastoma tumors (5, 10, and 15 mm in diameters) revealed the
heterogeneity of MAP2, PDGFRβ, and β-catenin expression in either forms
of tumor suggesting that phenotypic transitions occur in vivo. (C)
Immunofluorescence staining on frozen sections from mouse
neuroblastoma tumors (grown from either AD or AI cells) of 10 mm
diameter supports the flow cytometric and Western blot analysis of tumor
cell heterogeneity. (D) H&E staining of tumors reveals that both AD and AI
forms of Neuro2a cells gave rise to histopathologically similar tumors in
mice. (E) In vivo tumorigenic potential of the AD and AI phenotypes of
Neuro2a cells were compared by inoculating the mice with either form of
cell phenotype and measuring the tumor over time. Both cell types gave
rise to very large tumors and the growth rates were indistinguishable.
Data points expressed as mean±S.D. (n=12). Scale bar, 50µm.
tumors as well. Chemotherapeutic or growth factor receptor inhi-
bition in mice promoted initial loss of AD or AI heterogeneity,
respectively. Simultaneous targeting of both phenotypes with the
combination of these drugs gave way to the emergence of other
unique phenotypes.
Neuroblastoma is the most common pediatric solid extracra-
nial cancer in which lower-risk tumors are treatable and high-risk
disease is frequently fatal. Recent reports indicate the importance
of tumor initiating or stem-like cells in tumor resistance and tumor
recurrence (Rich, 2007; Wang et al., 2010). Cancer stem cells are
described for numerous solid tumors and the unique properties
of cancer stem cells suggest a significant role in tumor recurrence
following initial effective therapy (Eyler and Rich, 2008; Creighton
et al., 2009; Dave and Chang, 2009). The concept of a cancer stem
cell has gained much support due to the appeal of a theoretically
rare cell with indefinite tumorigenic potential for self-renewal and
differential sensitivity to chemotherapeutic agents. In contrast we
found that both AI and AD phenotypes were indistinguishable
with respect to the self-renewal potential, an undifferentiated state,
or expression of stem-like markers (or lack thereof). These find-
ings suggest that both AD and AI phenotypes display stem cell-like
characteristics, but we were unable to define a subset of specific
tumor stem cells.
The ability of tumor cells to adapt to the environment enables
tumors to evade surveillance of the immune system, survive unfa-
vorable conditions, or escape radio- or chemotherapy. This adap-
tation is most frequently described as a process of selection of the
fittest tumor cell clones generated by mutations as a consequence
of genetic instability (Marusyk and Polyak, 2010). Thus, under
the pressure of the immune response to a particular tumor anti-
gen, preferential outgrowth of tumor variants lacking the specific
antigen is frequently found (Zitvogel et al., 2006). This unidi-
rectional selection-based adaptation is one proposed adaptation
mechanism whereas EMT is another possible method. During
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EMT tumor cells undergo a transition to facilitate cell migration
(Creighton et al., 2009) and subsequently de-differentiate back
into epithelial cells once they have settled in the new location
(Thiery and Sleeman, 2006; Creighton et al., 2010). Our present
findings indicate that there are additional forms of transitions,
since we detected no changes in expression of markers indicative of
EMT or MET. It is possible that EMT and the transition we describe
(and perhaps other transitions as yet not described, but existing
in other tumors) represents the same general process of tumor
cell adaptation. This process could be governed by multiple fac-
tors including specific molecular programs, tumor origin, tumor
location, the abundance/scarcity of nutrients, and/or growth fac-
tors and other environmental cues (Magee et al., 2012). We believe
that the term “reversible adaptive plasticity” describes multiple
possible programs of bidirectional phenotypic conversion. In sup-
port of tumor cell conversion is the finding of in vivo switching
of melanoma cells between so called “proliferative” and “inva-
sive” cancer phenotypes (Hoek et al., 2008). These phenotypes
appear different from the ones we describe here since the tumors
with proliferative and invasive phenotypes display distinct rates of
in vivo growth whereas the tumor growth in our in vivo model
are indistinguishable in growth rate and responsive to environ-
mental cues. Alternatively, visibly different growth rates in vivo
in melanoma may suggest that melanoma cells cannot transition
in vivo as readily as neuroblastoma cells do.
Influence of the microenvironment on the plasticity of can-
cer cells is previously reported (Calabrese et al., 2007; Heddleston
et al., 2009; Martinez-Outschoorn et al., 2010; Allen and Louise
www.frontiersin.org August 2012 | Volume 2 | Article 82 | 11
Chakrabarti et al. Neuroblastoma heterogeneity and phenotypic plasticity
β- catenin  PDGFR β  Nestin/MAP2  
AD  
AI  
D
o
x
o
ru
b
ic
in
 t
re
a
te
d
 1
0
m
m
 
tu
m
o
rs
 
nestin 
nestin 
M
A
P
2
 
M
A
P
2
 
β-catenin 
β-catenin 
PDGFRβ 
PDGFRβ 
AD  
AI  
nestin 
nestin 
M
A
P
2
 
M
A
P
2
 
β-catenin 
β-catenin 
PDGFRβ 
PDGFRβ 
D
o
x
o
ru
b
ic
in
+
 M
e
tf
o
rm
in
 t
re
a
te
d
  
  
 
1
0
m
m
 t
u
m
o
rs
 
A
B
FIGURE 11 | Large doxorubicin and doxorubicin/metformin
double-resistant tumors resume phenotypic heterogeneity. Flow
cytometric analysis on large (10 mm diameter) mouse neuroblastoma
tumors treated with doxorubicin (A) and doxorubicin/metformin
(B) showed no remarkable difference in the expression of MAP2,
β-catenin, and PDGFRβ in the two forms of tumor (grown from either AD
or AI cells). Apparently either treatment displayed both AD (MAP2+) and
AI (MAP2−) phenotypes.
Jones, 2011). Our findings show adaptation of tumor cells to
chemotherapy, as cells displaying AD phenotype displayed greater
sensitivity to doxorubicin treatment compared to AI cells. The fact
that AD cells proliferate more rapidly than AI cells may explain why
doxorubicin was more effective in the former, since doxorubicin
inhibits DNA replication of highly proliferative cells (Kotchetkov
Frontiers in Oncology | Pediatric Oncology August 2012 | Volume 2 | Article 82 | 12
Chakrabarti et al. Neuroblastoma heterogeneity and phenotypic plasticity
et al., 2003). The finding that the balance of heterogeneous cell
populations present in the tumor in vivo is temporarily altered by
doxorubicin therapy (with or without metformin) suggests that
tumor cell plasticity is a dynamic process that protects tumor cells
from sudden unfavorable changes in their environment. The envi-
ronmental factors and mechanisms that “spontaneously” drive the
phenotypic conversion and maintain the cellular heterogeneity in
the absence of chemotherapeutic agents are unknown at present.
Nevertheless, understanding the mechanism of the present find-
ings should have critical therapeutic implications from pharma-
cologic and immunologic perspectives and may be an important
determinant of tumor prognosis.
In conclusion, the work presented shows that neuroblastoma
cells are plastic, dynamic, and respond to their niche. The cells
acquire features needed to optimize their ability to survive and
the findings described have important implications for target-
ing tumor cells in transitional states. It is evident that tumor
cell sensitivity under specific niches or conditions that favor one
phenotype cannot be generalized to predict clinical therapeu-
tic susceptibility. The clinical behavior and successful treatment
of neuroblastoma may be dependent on the reversible adaptive
plasticity described.
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